Global benefit - Risk assessment in designing clinical trials and some statistical considerations of the method

Pharmaceutical Statistics

Volumn 7, Issue 3, 2008, Pages 170-178

  Pritchett, Yili Lu ^a   Tamura, Roy ^b  

^a ABBOTT LABORATORIES   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Benefit risk analysis; Clinical trial design; Global benefit risk assessment

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO;

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; OUTCOME ASSESSMENT; REMISSION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS AS TOPIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK ASSESSMENT;

EID: 52649127401     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.281     Document Type: Article

References (12)

1. Borer JS.'t-PA, the principles of drug approval' editorials. New England Journal of Medicine 1987; 26:1659-1661.
2. Payne JT, Loken MK. A survey of the benefits and risks in the practice of radiology. CRC Critical Reviews in Clinical Radiology and Nuclear Medicine 1975; 6:425-439.
3. Chang RW, Fineberg HV. Risk-benefit considerations in the management of polymyalgia rheumatica. Medical Decision Making 1983; 3:459-475.
4. Hilden J. Reporting clinical trials from the view-point of a patient's choice of treatment. Statistics in Medicine 1987; 6:745-752.
5. Chuang-Stein C, Mohberg NR, Sinkula MS. Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials. Statistics in Medicine 1991; 10:1349-1359.
6. Entsuah R, Gorman JM. Global benefit-risk assessment of antidepressants: vanlafaxine XR and fluoxetine, Journal of Psychiatric Research 2002; 36:111-118.
7. Entsuah R, Gao B. Global benefit-risk evaluation of antidepressant action: comparison of pooled data for venlafaxine, SSRIs and placebo. CNS SPECTRUMS 2002; 7:882-888.
8. Fava M, Evins AE, David D, Schoenfeld D. The problem of the placebo response in clinical trails for psychiatric disorder: culprits, possible remedies, and a novel study den approach. Psychotherapy and Psychosomatics 2003; 72:115-127.
9. Serfling RJ. Approximation theorems of mathematical statistics. Wiley: New York, 1980.
10. Bross IDJ. How to use RIDIT analysis. Biometrics 1958; 14:18-38.
11. Agresti A. Categorical Data Analysis. Wiley: New York, 1990.
12. Stokes ME, Davis CS, Koch GG. Categorical data analysis using the SAS system. SAS Institute Inc., 2000; 68-73.